Mpox AND vaccines AND “benefits and harms” OR safety OR efficacy OR effectiveness OR “adverse events”

Acharya, A., Kumar, N., Singh, K., & Byrareddy, S. N. (2024). Mpox in MSM: Tackling Stigma, Minimizing Risk Factors, Exploring Pathogenesis, and Treatment Approaches. Biomedical Journal, 100746. https://doi.org/10.1016/j.bj.2024.100746

Banik, A., Umpo, M., & Sinha, S. (n.d.). Monkeypox: A Global Challenge-An Overview.

Bashwira, M.-R., Mihigo, I. M., & Duclos, D. (2024). Key Considerations: Mpox, Mining, and Vulnerabilities of Women and Children in eastern DRC.https://www.researchgate.net/profile/Ashmita-Banik-2/publication/385280478

Braimah, J. A., Achore, M., Dery, F., Ayanore, M. A., Bisung, E., & Kuuire, V. (2024). Do self-rated health and previous vaccine uptake influence the willingness to accept MPOX vaccine during a public health emergency of concern? A cross-sectional study. PLOS Global Public Health, 4(8), e0003564. https://doi.org/10.1371/journal.pgph.0003564

Delight, E. A., Brunn, A. A., Ruiz, F., Gerard, J., Falconer, J., Liu, Y., Bah, B., Bett, B., Uzochukwu, B., & Oloko, O. K. (2024). Gaps and Opportunities for Data Systems and Economics to Support Priority Setting for Climate-Sensitive Infectious Diseases in Sub-Saharan Africa: A Rapid Scoping Review. medRxiv, 2024–09. https://www.medrxiv.org/content/10.1101/2024.09.20.24314043v1.full.pdf

Gashema, P., Musafiri, T., Ndahimana, F., Iradukunda, H., Saramba, E., Nyakatswau, S. T., Gahamanyi, N., Iradukunda, P. G., Ahmed, A., & Dzinamarira, T. (2024). Mpox in East Africa: Learning from COVID-19 and Ebola to Strengthen Public Health Responses. Viruses, 16(10), 1578. https://doi.org/10.3390/v16101578

Hammershaimb, E. A., & Campbell, J. D. (2024). Vaccine Development. Pediatric Clinics, 71(3), 529–549. https://www.pediatric.theclinics.com/action/showPdf?pii=S0031-3955%2824%2900029-4

Lawrence, A. (2024). Assessing Vaccine Intentions, Knowledge, Self-Efficacy, and Trust: A Cross-Sectional Study on Perceptions of Monkeypox Vaccination and Public Health Risk Awareness in Makurdi, Benue State, Nigeria. Cureus, 16(10), e72131. doi: 10.7759/cureus.72131

Manirambona, E., Khan, S. H., Siddiq, A., Albakri, K., Salamah, H. M., Hassan, N. A. I. F., Musa, S. S., & Dhama, K. (2024). Intriguing insight into unanswered questions about Mpox: Exploring health policy implications and considerations. Health Research Policy and Systems, 22(1), 37. https://link.springer.com/content/pdf/10.1186/s12961-024-01123-9.pdf

Maniskas, S., Marty, M., & Truong, A. (2024). The Challenge of Mpox Diagnosis for the Colorectal Surgeon. World Journal of Colorectal Surgery, 13(4), 141–143.https://journals.lww.com/wjcs/fulltext/2024/13040/the_challenge_of_mpox_diagnosis_for_the_colorectal.7.aspx

Mektebi, A., Elsaid, M., Yadav, T., Abdallh, F., Assker, M., Siddiq, A., Sayad, R., Saifi, M., & Farahat, R. A. (2024). Mpox vaccine acceptance among healthcare workers: A systematic review and meta-analysis. BMC Public Health, 24(1), 4. https://link.springer.com/content/pdf/10.1186/s12889-023-17186-2.pdf

Musuka, G., Moyo, E., Tungwarara, N., Mhango, M., Pierre, G., Saramba, E., Iradukunda, P. G., & Dzinamarira, T. (2024). A critical review of mpox outbreaks, risk factors, and prevention efforts in Africa: Lessons learned and evolving practices. IJID Regions, 100402 https://doi.org/10.1016/j.ijregi.2024.100402.

Phiri, S., & Lusaka, Z. (n.d.). Mpox in Zambia: An Overview of Pathogenesis, Diagnosis, and Public Health Implications.

Pitcock, C. T., Van Sickels, N., & Romanelli, F. (2024). Advances in recognizing, treating, and preventing mpox infection. JAPhA Pharmacotherapy, 1(2). https://www.japhapharmacotherapy.org/article/S2949-9623(23)00004-9/pdf

Poy, D., & Tohidfar, M. (2024). Molecular Docking and Dynamic Simulation on Investigation and Introduction of some Secondary Metabolites of Medicinal Plants with Antiviral Activity and Effective Vitamins for the Treatment of MPox. Journal of Applied Biotechnology Reports, 11(2), 1289–1300. https://www.biotechrep.ir/article_200161_6a8515aeac4ae73b415b1b4cda97eaa1.pdf

Shankar, M., Hartner, A.-M., Arnold, C. R., Gayawan, E., Kang, H., Kim, J.-H., Gilani, G. N., Cori, A., Fu, H., & Jit, M. (2024). Mathematical modelling to inform outbreak response vaccination. arXiv Preprint arXiv:2410.13923. https://arxiv.org/pdf/2410.13923

Sinumvayo, J. P., Munezero, P. C., Tope, A. T., Adeyemo, R. O., Bale, M. I., Mutsaka-Makuvaza, M. J., Daba, T. M., Nyandwi, J. B., Nzungize, L., & Mutumwinka, D. (2024). Vaccination and vaccine-preventable diseases in Africa. Scientific African, e02199. https://doi.org/10.1016/j.sciaf.2024.e02199

Tambo, E., Noungoue Ngounou, P. J., Njobet, M. P., Tappa, N. T., Ngogang, J., Hunter, M., Shaw, S. Y., Rimoin, A. W., Placide, M., & Kindrachuk, J. (2024). Assessment of risk perception and determinants of mpox for strengthening community engagement in local populations in Cameroon. medRxiv, 2024–03. https://www.medrxiv.org/content/10.1101/2024.03.20.24304629v1

Savinkina, A., Kindrachuk, J., Bogoch, I. I., Rimoin, A. W., Hoff, N. A., Shaw, S. Y., Pitzer, V. E., Mbala-Kingebeni, P., & Gonsalves, G. S. (2024). Modelling vaccination approaches for mpox containment and mitigation in the Democratic Republic of the Congo. The Lancet. Global health, 12(12), e1936–e1944. https://doi.org/10.1016/S2214-109X(24)00384-X

Charniga, K., McCollum, A. M., Hughes, C. M., Monroe, B., Kabamba, J., Lushima, R. S., Likafi, T., Nguete, B., Pukuta, E., Muyamuna, E., Muyembe Tamfum, J. J., Karhemere, S., Kaba, D., & Nakazawa, Y. (2024). Updating Reproduction Number Estimates for Mpox in the Democratic Republic of Congo Using Surveillance Data. The American journal of tropical medicine and hygiene, 110(3), 561–568. https://doi.org/10.4269/ajtmh.23-0215

Chaturvedi, M., Rodiah, I., Kretzschmar, M., Scholz, S., Lange, B., Karch, A., & Jaeger, V. K. (2024). Estimating the relative importance of epidemiological and behavioural parameters for epidemic mpox transmission: a modelling study. BMC medicine, 22(1), 297. https://doi.org/10.1186/s12916-024-03515-8

Schwartz D. A. (2024). High Rates of Miscarriage and Stillbirth among Pregnant Women with Clade I Mpox (Monkeypox) Are Confirmed during 2023-2024 DR Congo Outbreak in South Kivu Province. Viruses, 16(7), 1123. https://doi.org/10.3390/v16071123

Larivière, Y., Garcia-Fogeda, I., Zola Matuvanga, T., Isekah Osang'ir, B., Milolo, S., Meta, R., Kimbulu, P., Robinson, C., Katwere, M., McLean, C., Hens, N., Matangila, J., Maketa, V., Mitashi, P., Muhindo-Mavoko, H., Van Geertruyden, J. P., & Van Damme, P. (2024). Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo. The Journal of infectious diseases, 229(4), 1068–1076. https://doi.org/10.1093/infdis/jiad350

Gashema, P., Musafiri, T., Ndahimana, F., Iradukunda, H., Saramba, E., Nyakatswau, S. T., Gahamanyi, N., Iradukunda, P. G., Ahmed, A., Dzinamarira, T., & Muvunyi, C. M. (2024). Mpox in East Africa: Learning from COVID-19 and Ebola to Strengthen Public Health Responses. Viruses, 16(10), 1578. https://doi.org/10.3390/v16101578

Schmidt-Sane, M., Adegoke, O., Abbas, S., Lawanson, A. O., Kunnuji, M., Jegede, A., & MacGregor, H. (2024). Infrastructures of epidemic response: Mpox and everyday repair work in southwestern Nigeria. Social science & medicine (1982), 358, 117246. https://doi.org/10.1016/j.socscimed.2024.117246